Source Natural Foods & Herbal Supplements Ltd Falls to 52-Week Low of Rs.118

Stock Price Movement and Market Context

On 9 Mar 2026, Source Natural Foods & Herbal Supplements Ltd’s share price touched an intraday low of Rs.118, representing a decline of 4.34% on the day and a new 52-week low. The stock’s intraday high was Rs.133.7, indicating a wide trading range and high volatility of 6.24% based on the weighted average price. Over the past two trading sessions, the stock has fallen by 9.15%, underperforming its Pharmaceuticals & Biotechnology sector by 2.96% on the day.

The broader market environment has been challenging, with the Sensex opening sharply lower at 77,056.75, down 2.36% from the previous close, and continuing a three-week losing streak with a cumulative decline of 6.87%. The Sensex is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, signalling some underlying support. Meanwhile, the INDIA VIX index reached a new 52-week high, reflecting elevated market uncertainty.

Technical Indicators and Moving Averages

Source Natural Foods & Herbal Supplements Ltd is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad weakness across technical indicators suggests sustained downward momentum. The stock’s 52-week high stands at Rs.216, highlighting the extent of the recent decline from its peak.

Financial Performance and Valuation Metrics

Despite the recent price weakness, the company has reported positive quarterly results for nine consecutive quarters, with the latest quarter’s net sales reaching a record Rs.20.30 crores. Return on equity (ROE) stands at 12.4%, and the stock trades at a price-to-book value of 3.6, which is considered fair relative to its peers. However, the company’s long-term growth has been modest, with a compound annual growth rate (CAGR) of just 1.19% in operating profits over the past five years.

Over the last year, the stock has generated a negative return of 14.14%, significantly underperforming the Sensex, which gained 3.77% during the same period. Profit growth over the past year was 6.5%, but the price-to-earnings-to-growth (PEG) ratio is elevated at 4.4, indicating that the stock’s price performance has not kept pace with earnings growth.

Mojo Score and Analyst Ratings

The company’s Mojo Score currently stands at 26.0, reflecting a Strong Sell rating, which was upgraded from a Sell on 5 Feb 2026. This downgrade reflects concerns about the company’s weak long-term fundamental strength and below-par performance relative to the broader market and its sector peers. The market capitalisation grade is rated 4, indicating a smaller market cap relative to larger, more liquid stocks.

Shareholding and Corporate Structure

Promoters remain the majority shareholders of Source Natural Foods & Herbal Supplements Ltd, maintaining significant control over the company’s strategic direction. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance amid evolving market conditions.

Comparative Performance and Sector Context

Over the past three years, the stock has underperformed the BSE500 index across multiple time frames, including the last three months and one year. This underperformance is notable given the company’s positive quarterly results and steady sales growth. The stock is currently trading at a discount compared to its peers’ average historical valuations, which may reflect market caution given the company’s growth profile and recent price volatility.

Summary of Key Metrics

To summarise, Source Natural Foods & Herbal Supplements Ltd’s share price decline to Rs.118 marks a significant technical low within a broader context of subdued long-term growth and relative underperformance. The stock’s volatility and trading below all major moving averages underscore the current market sentiment. While the company continues to report positive quarterly sales and profits, the modest CAGR in operating profits and elevated PEG ratio highlight challenges in translating earnings growth into sustained share price appreciation.

Market conditions remain volatile, with the Sensex experiencing a notable correction and increased uncertainty as reflected by the INDIA VIX. Investors and analysts will continue to monitor the company’s financial metrics and sector dynamics as the Pharmaceuticals & Biotechnology industry navigates evolving market trends.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today